Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Arcutis Biotherapeutics Inc (Arcutis) is a commercial-stage medical dermatology company that develops innovative products for immune-mediated dermatological diseases and conditions. The company offers products such as ZORYVE (roflumilast) cream for the treatment of plaque psoriasis and atopic dermatitis; ZORYVE (roflumilast) topical foam which targets seborrheic dermatitis and plaque psoriasis include headache, diarrhea, nausea, and nasopharyngitis. Its pipeline products include ARQ-151for the treatment of atopic dermatitis and plaque psoriasis; and ARQ-154 which treats seborrheic dermatitis, scalp and body psoriasis, hidradenitis suppurativa, and vitiligo; and ARQ-234 for atopic dermatitis. Arcutis is headquartered in California, the US.
Headquarters
United States of America
Address
3027 Townsgate Road, Suite 300, Westlake Village, California, 91361
Website
arcutis.com
Telephone
1 805 4185006
No of Employees
354
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARQT (NASD)
Revenue (2024)
$376.1M
91.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
88.5%
(2024 vs 2023)
Market Cap*
$3.2B
Net Profit Margin (2024)
XYZ
94.0%
(2024 vs 2023)
* As of and is in US$
Arcutis Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| ZORYVE (roflumilast) Cream: Plaque Psoriasis and Atopic Dermatitis | ZORYVE |
| ZORYVE (roflumilast) Topical Foam: Seborrheic Dermatitis and Plaque Psoriasis | |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company received approval from the U.S. Food and Drug Administration for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas. |
| 2026 | Others | In January, the company terminated promotion agreement with Kowa Pharmaceuticals America, Inc. |
| 2025 | Regulatory Approval | In October, the company received approval from the US Food and Drug Administration for ZORYVE (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age. |
Competitor Comparison
| Key Parameters | Arcutis Biotherapeutics Inc | Johnson & Johnson | Pfizer Inc | AbbVie Inc | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | - | New Brunswick | New York City | North Chicago | Princeton |
| State/Province | California | New Jersey | New York | Illinois | New Jersey |
| No. of Employees | 354 | 138,200 | 75,000 | 57,000 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick J. Heron | Chairman | Executive Board | 2019 | 54 |
| Todd Franklin Watanabe | Chief Executive Officer; President | Senior Management | 2017 | 58 |
| Latha Vairavan | Chief Financial Officer | Senior Management | 2025 | - |
| Bethany Dudek | Chief Technology Officer | Senior Management | - | - |
| Mas Matsuda | Executive Vice President; Chief Legal Officer; Company Secretary | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer